(Total Views: 395)
Posted On: 11/21/2019 10:33:31 AM
Post# of 153822
“So, IMO, we should have a ~$1/share very soon, without licensing NASH, based on the "Strong" keyword in the PR.”
“Should” is the key word, as this is is CYDY, which does not respond to news like other biotechs. Why? Well, CYDY doesn’t have any cash, a low SP, and is on the OTC. The most we can hope for is that this data gets CYDY a partnership with an upfront payment.
“Should” is the key word, as this is is CYDY, which does not respond to news like other biotechs. Why? Well, CYDY doesn’t have any cash, a low SP, and is on the OTC. The most we can hope for is that this data gets CYDY a partnership with an upfront payment.
(2)
(0)
